Clinilabs is proud to attend the International Congress of Parkinson’s Disease and Movement Disorders in Seoul, South Korea, marking our first participation in this premier global event dedicated to advancing the science and treatment of movement disorders.
As a CNS-focused CRO, Clinilabs is committed to accelerating the development of innovative therapies for patients living with Parkinson’s disease and other neurodegenerative disorders. These conditions present significant challenges for patients, families, and healthcare systems worldwide, underscoring the urgent need for continued scientific innovation and clinical research.
Our participation reflects Clinilabs’ dedication to supporting sponsors developing the next generation of therapies for neurological disorders. With deep expertise across CNS indications and specialized capabilities in clinical development, biomarker assessments, neurophysiology, digital measures, and patient-centered research, we help advance promising treatments from early development through pivotal clinical trials.
We look forward to engaging with researchers, clinicians, industry leaders, and innovators from around the world as we explore new opportunities to advance research and improve outcomes for individuals affected by Parkinson’s disease and other movement disorders.
Let’s discuss how Clinilabs can help move your CNS research program forward, from early development through pivotal trials. Book a meeting with us today.
